Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
H. Wilke(Kliniken Essen-Mitte), Kei Muro(Aichi Cancer Center), Eric Van Cutsem(KU Leuven), Sang-Cheul Oh(Korea University Medical Center), G. Bodoky(Unified Szent István and Szent László Hospital), Yasuhiro Shimada(National Cancer Center), Shuichi Hironaka(Chiba Cancer Center), Naotoshi Sugimoto(Osaka International Cancer Institute), Oleg Lipatov(Republican Oncological Clinical Dispensary), Tae‐You Kim(Seoul National University Hospital), David Cunningham(Royal Marsden Hospital), Philippe Rougier(Université Paris Cité), Yoshito Komatsu(Hokkaido University), Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center), Michael Emig(Eli Lilly (Germany)), Roberto Carlesi(Eli Lilly (Italy)), David Ferry(New Cross Hospital), Kumari Chandrawansa(Eli Lilly (United States)), Jonathan D. Schwartz, Atsushi Ohtsu(National Cancer Center Hospital East)
Cited by 2,460